Elekta pledges $1 million to support RT research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 5
Volume 18
Issue 5

Elekta has promised $1 million to the Radiation Oncology Institute, a campaign spearheaded by the American Society for Radiation Oncology to raise awareness of radiation therapy.

Elekta has promised $1 million to the Radiation Oncology Institute, a campaign spearheaded by the American Society for Radiation Oncology to raise awareness of radiation therapy.

To date, the institute has raised $7 million of its $10 million goal. ASTRO initially kicked in $5 million that was matched by $3 million from ASTRO members. Other contributors include Varian Medical Systems at $2 million.

The institute will conduct objective research on the specialty to document the value, safety, efficacy and cost effectiveness of radiation therapy, according to Colleen A. Lawton, MD, campaign cochair.

Recent Videos
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
Related Content